METHODS: This study analyzed a cohort of patients with COPD who had entered a previously initiated prospective cohort study involving patients with COPD and/or asthma at the Prince of Wales Hospital between 2017 and 2019.
RESULTS: Patients with COPD were enrolled (N = 220, mean age 74.3 years, 97 % male). Twelve months prior to baseline assessment, 66 % of patients were on MITT, 17 % on long-acting muscarinic antagonists (LAMAs)/long-acting beta-agonists (LABAs), and 7 % on inhaled corticosteroids (ICS)/LABA. Compared with ICS/LABA or LAMA/LABA, more patients on MITT experienced ≥1 exacerbation (26.7 %, 10.5 %, 39.7 %, respectively). Patients on MITT also had a higher mean (SD) COPD Assessment Test score (9.4 [5.9]) and modified Medical Research Council Dyspnea Scale score (1.7 [0.7]) and incurred the most COPD-related and total HCRU costs. Compared with patients with EOS ≤300 cells/μL, those with EOS >300 cells/μL had a higher number of exacerbations.
CONCLUSIONS: Patients with COPD in Hong Kong treated with MITT presented more severe disease profiles and incurred higher costs. These data can be used for decision making in patients with moderate-to-severe COPD in Hong Kong.
方法:本研究分析了2017-2019年间在威尔士亲王医院进行的一项前瞻性队列研究的COPD患者队列。
结果:纳入COPD患者(N=220,平均年龄74.3岁,97%男性)。基线评估前12个月,66%的患者接受了MITT,17%的长效毒蕈碱拮抗剂(LAMA)/长效β-激动剂(LABA),吸入性皮质类固醇(ICS)/LABA为7%。与ICS/LABA或LAMA/LABA相比,更多的MITT患者经历了≥1次加重(26.7%,10.5%,39.7%,分别)。接受MITT的患者的平均(SD)COPD评估测试评分(9.4[5.9])和改良的医学研究理事会呼吸困难量表评分(1.7[0.7])也较高,并且发生的COPD相关费用和HCRU总成本最高。与EOS≤300细胞//μL的患者相比,EOS>300个细胞//μL的患者加重次数较多.
结论:在香港,接受MITT治疗的COPD患者病情更为严重,费用更高。这些数据可用于香港中重度COPD患者的决策。